SNORD114-24: A Potential Drug Target and Biomarker for Epilepsy

Target Name: SNORD114-24

NCBI ID: G767604

SNORD114-24

Other Name(s): 14q(II-24) | small nucleolar RNA, C/D box 114-24 | Small nucleolar RNA, C/D box 114-24

SNORD114-24: A Potential Drug Target and Biomarker for Epilepsy

Epilepsy is a chronic and debilitating neurological disorder that affects millions of people worldwide. Despite being one of the most common brain disorders, it remains to be understood fully, and current treatments are often limited in their effectiveness. Therefore, the identification of new drug targets and biomarkers for the treatment of epilepsy is of great importance.

SNORD114-24 is a non-coding RNA molecule that is located on chromosome 14q21. It has been shown to be involved in the regulation of a variety of gene expression, including those related to epilepsy. Therefore, it is a promising candidate for drug targeting in the treatment of epilepsy.

One of the key features of SNORD114-24 is its ability to interact with the protein p53. p53 is a well-known tumor suppressor protein that plays a critical role in regulating gene expression and cell survival. SNORD114-24 has been shown to physically interact with p53 and regulate its activity. This interaction between SNORD114-24 and p53 suggests that it may be a useful target for the treatment of epilepsy.

Another potential mechanism by which SNORD114-24 may be involved in the development of epilepsy is its role in the regulation of ion channels in the brain. SNORD114-24 has been shown to be involved in the regulation of the trafficking of a type of ion channel called TRPV4, which is known to be involved in the regulation of pain and inflammation. Alterations in TRPV4 function have been implicated in the development of epilepsy. Therefore, targeting SNORD114-24 with drugs that modulate TRPV4 function may be a potential approach to the treatment of epilepsy.

In addition to its potential role in the regulation of ion channels, SNORD114-24 is also involved in the regulation of a protein called NF-kappa-B. NF-kappa-B is a transcription factor that plays a role in the regulation of a wide variety of cellular processes, including inflammation and pain. SNORD114-24 has been shown to be involved in the regulation of NF-kappa-B activity, which suggests that it may be involved in the development of epilepsy.

Given the potential involvement of SNORD114-24 in the regulation of ion channels and NF-kappa-B activity, it is a promising candidate for drug targeting in the treatment of epilepsy. Further research is needed to fully understand the role of SNORD114-24 in the development and treatment of epilepsy, as well as the development of new drug targets and biomarkers for the disorder.

Protein Name: Small Nucleolar RNA, C/D Box 114-24

The "SNORD114-24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets